# Incidence and risk factors of Hyperglycemia in Very Low Birth Weight infants.

#### **THESIS**

Submitted for partial fulfillment of the M.Sc. degree in Pediatrics

Submitted by:

Asmaa Gamal Abd El - Aziz Ahmed (M.B.B.Ch.)

Under supervision of:

#### Prof. Dr. Abdel Rahman Ahmed Abdel Razek

Assisstant Professor of Pediatrics Faculty of Medicine Cairo University

### Dr. Dina Mohammed Akmal

Lecturer of Pediatrics Faculty of Medicine Cairo University

### Dr. Noha Musa Azab

Lecturer of Pediatrics Faculty of Medicine Cairo University

Faculty of Medicine Cairo University 2016

# **List of Contents**

Content	Page No
Acknowledgement	I
Abstract	II
List of Tables	V
List of Figures	VIII
List of Abbreviations	IX
Introduction	1
Aim of the Work	3
Review of Literature:	4
Chapter (I): Introduction on Prematurity	4
Chapter (II): Hyperglycemia in preterm neonates	25
Patients and Methods	51
Results	55
Discussion	78
Summary	88
Conclusion	91
Recommendations	92
References	93
Arabic Summary	106

### **Acknowledgement**

First of all, I would like to thank **Allah**, the most Benificent, Forgiving and Merciful, who gave me the power to finish this work.

I am greatly honored to express my feelings of appreciation and sincere gratitude to **Prof. Dr. Abdel Rahman Ahmed Abdel Razek,** assistant Professor of Pediatrics, Faculty of Medicine, Cairo University, for giving me the chance of working under his supervision. He is always correcting and guiding me all the way. His scientific and moral support made it possible for this work to see the light.

I offer my deepest appreciation to **Dr. Dina Mohamed Akmal,** Lecturer of Pediatrics , Faculty of Medicine, Cairo University, for her valuable supervision , guidance and continous support .

I would like to express my greatest and deepest appreciation to **Dr. Noha Musa Azab**, Lecturer of Pediatrics Endocrinology, Faculty of Medicine, Cairo University, for her valuable effort and endless help in this work. She gave me too much of her time. I am in great debt to her.

Also I want to thank **Prof. Dr. Salma El Houshy** and **Prof. Dr. Nancy Abu Shady** for giving me the honor of discussing this work, many appreciations for their help& time

I want to take this chance to express my thanks, respect and love to my parents, family for their encouragement.

Asmaa Gamal Abd El-Aziz.

## **Abstract**

- Premature infants often develop hyperglycemia. Stress, intravenous glucose, neonatal steroids, and inotropes may increase the incidence of hyperglycemia in premature infants. In very low birth weight (VLBW) infants( birthweight <1,500g) hyperglycaemia is associated with increased rates of morbidity ( late onset sepsis , intraventricular hemorrhage , necrotizing enterocolitis ) and mortality.</li>
- Our study aim to study the incidence of hyperglycemia in very low birth weight infants and relation to antenatal risk factors ( placental insufficiency , antenatal steroids in pregnant mothers , premature rupture of membranes ) and post natal risk factors ( receiving steroids , inotropes , intravenous glucose, total parenteral nutrition , milk intake & infection in 1<sup>st</sup> week of life) and relation of hyperglycemia to complications( late onset sepsis, intraventricular hemorrhage, necrotizing enterocolitis), prolonged hospitalization >28 days and outcome of these neonates.
- This cross-sectional comparative study carried out in the NICU of El-Kasr El-Aini hospital, Cairo University & Abu El Rish El Monira Hospital between February 2015 and July 2015 included 60 VLBW neonates who were admitted since birth to NICU. Random blood glucose was measured during 1<sup>st</sup> week of life (checked every 3 hours in the 1<sup>st</sup> 48 hours, then every 6 hours for the next 5 days) using glucometer BG strips through a heel pin prick. Thorough maternal history taking focusing on maternal diseases causing placental insufficiency, antenatal steroids intake, mode of delivery, PROM. Assessment of birth weight, gestational age, Apgar score at 1,5 and 10 minutes, medications, nutritional assessment and IV fluid intake

during  $1^{\rm st}$  week of life . Assesment of development of complications was performed .

• In our study, 40 neonates (66.7%) developed hyperglycemia during 1<sup>st</sup> week of life. The mean gestational age of studied neonates was 30.1  $\pm 1.8$ weeks, mean birth weight was 1.285± 0.17 kg, mean Apgar score at 1 min , 5min , 10 min was  $3.4 \pm 1.7$  ,  $6.7 \pm 1.6$  and  $8.2 \pm 1.4$  respectively. Among hyperglycemic cases 20 neonates (50%) developed severe hyperglycemia while 16 (40%) developed moderate hyperglycemia and only 4 (10%) had hyperglycemia. Among hyperglycemic cases, 34 (85%) developed hyperglycemia during 1<sup>st</sup> 48 hours of life, while 6 (15%) had hyperglycemia after 48 hrs of life. There was statistically significant relation between hyperglycemia and gestational age, birth weight, placental insufficiency during pregnancy, receiving inotropes and milk intake after birth (p=0.05, 0.042, 0.044, 0.001 and 0.007 respectively). There was statistically significant relation between hyperglycemia and LOS, IVH, death (p= 0.001, 0.003 & 0.022 respectively). There was statistically significant relation between severity of hyperglycemia and infection in 1st week and IVH (p=0.025 & 0.05 respectively). There was no statistically significant relation hyperglycemia and gender, APGAR score, mode of delivery, between antenatal steroids, PROM, post natal steroid intake, sepsis in the first week, mean dextrose, amino acid and lipid infusions (p > 0.05). There was statistically significant relation between hyperglycemia and no NEC, prolonged hospitalization  $\geq$ 28 days (p= 0.825 & 0.271 respectively).

Conclusion of our study: There was high incidence of hyperglycemia in VLBW (66.7%). There was statistically significant relation between hyperglycemia and different neonatal parameters (gestational age, birth

weight), risk factors (placental insufficiency , receiving inotropes , milk intake after birth), complications (LOS , IVH, death)

• Key words: Hyperglycemia, Very Low Birth Weight infants.

# **List of Tables**

Table No	Table's Title	Page N <u>o</u>
1	Country data and rankings for preterm rate, birth and death data, 2012.	6
2	Short and Long Term Complications Of prematurity.	12
3	Distribution of glucose transporters.	29
4	Metabolic transition at birth.	32
5	Causes of Hyperglycemia .	33
6	Adverse Outcomes of Hyperglycemia.	37
7	Insulin infusion rate.	48
8	Titrate of insulin.	49
9	Gender, mode of delivery, number of babies within the study.	55
10	Gestational age, birth weight and Apgar score within the study group.	56
11	Hyperglycemia in studied neonates.	56
12	Treatment of hyperglycemia in the study.	58
13	Hyperglycemia in relation to GA, birth weight, APGAR score within the study.	59
14	Hyperglycemia in relation to gender, mode of delivery, number of babies.	59
15	Risk factors of hyperglycemia in the studied neonates.	60
16	Dextrose infusion, lipid infusion and amino acid infusion, total calories of lipid and amino acid during 1 <sup>st</sup> week of life.	60
17	Antenatal risk factors (placental insufficiency, antenatal steroids in pregnant mothers $\mbox{,PROM}$ ) in relation to hyperglycemia.	61
18	Post natal risk factors (inotropes, steroids, TPN,	62

	milk intake, infection during 1 <sup>st</sup> week of life) in relation to hyperglycemia.	
19	Dextrose infusion, lipid infusion and amino acid infusion, total calories of lipid and amino acid during 1 <sup>st</sup> week of life in relation to hyperglycemia.	62
20	Complications (LOS, IVH, NEC), prolonged hospitalization >28 days and outcome in studied neonates.	63
21	Complications (LOS, IVH, NEC), Prolonged hospitalization >28 days, outcome in relation to hyperglycemia.	64
22	Correlation of blood glucose level with different neonatal parameters.	65
23	Degree of hyperglycemia within hyperglycemic group .	66
24	Degree of hyperglycemia in relation to gender, mode of delivery, number of babies.	67
25	Degree of hyperglycemia in relation to GA, birth weight, APGAR score at 1 min, 5 min, 10 min.	67
26	Relation between degree of hyperglycemia and mode of treatment.	68
27	Antenatal risk factors (placental insufficiency, antenatal steroids in pregnant mothers, PROM) in relation to degree of hyperglycemia.	68
28	Post natal risk factors (inotropes, steroids, TPN, milk intake, infection during $1^{st}$ week of life) in relation to degree of hyperglycemia.	69
29	post natal risk factors (Total mean dextrose infusion , Total lipid infusion , Total aa .infusion , Total lipid calories, Total amino acid calories during 1 <sup>st</sup> week of life ) in relation to degree of hyperglycemia .	70
30	Complications (LOS, IVH, NEC), prolonged	71
	hospitalization >28 days and outcome in relation to	

	degree of hyperglycemia .	
31	Onset of hyperglycemia in studied neonates .	72
32	Onset of hyperglycemia in relation to gender, mode of delivery, number of babies.	73
33	Onset of hyperglycemia in relation to GA, birth weight, apgar score at 1 min, 5 min & 10 min.	73
34	Antenatal risk factors (placental insufficiency, antenatal steroids in pregnant mothers, PROM ) in relation to onset of hyperglycemia.	74
35	Post natal risk factors (inotropes, steroids, TPN, milk intake, infection during 1 <sup>st</sup> week of life) in relation to onset of hyperglycemia.	75
36	Post natal risk factors (Total mean dextrose infusion, Total lipid infusion, Total aa .infusion, Total lipid calories, Total amino acid calories during 1 <sup>st</sup> week of life ) in relation to onset of hyperglycemia.	75
37	Complications (LOS, IVH, NEC), prolonged hospitalization >28 days, outcome in relation to onset of hyperglycemia.	76

# **List of figures**

Figure N <u>o</u>	Figure's Title	Page No
1	Preterm births by gestational age and region for year 2010	5
2	All preterm and late preterm births, as percentage of all births, 1990-2013	7
3	Percentage preterm births, by plurality, 2012	8
4	Estimated distribution of causes of 3.1 million neonatal deaths in 193 countries in 2010	22
5	Energy and nutrient substrates transfer to fetus	28
6	<b>Energy substrates transported to and deposited</b> in the fetus	30
7	Effects of hormone signaling on hepatic glucose metabolism	31
8	Management of neonatal hyperglycemia	46
9	Frequency of hyperglycemia in studied neonates.	56
10	Mean blood glucose levels in hyperglycemic & euglycemic patients (using highest reading in daily measures).	57
11	Treatment of hyperglycemia in the study.	58
12	Degree of hyperglycemia within hyperglycemic group .	66
13	Onset of hyperglycemia in studied neonates.	72

# **List of Abbreviations**

The Abbreviation	Refers to
AAP	<b>American Academy of Pediatrics</b>
BG	Blood glucose
BPD	Bronchopulmonary dysplasia
BP	Blood pressure
BW	Birth weight
CBC	Complete blood count
CKD	Chronic kidney disease
CLD	Chronic lung disease
CNS	Central nervous system
CPAP	Continous positive airway pressure
CP	Cerepral palsy
CRP	C –reactive protein
CS	Cesarean section
DIC	Disseminated intravascular coagulation
DW	Dextrose water
ELBW	Extremely low birth weight
EONS	Early onset neonatal sepsis
GA	Gestational age
GIR	Glucose infusion rate
GLUT	Glucose transporter
GU	Genito-urinary
HIV	Human immune dificiensy virus
IGF	Insulin like growth factor
Iu	International unit
IVH	Intraventricular hemorrhage
IV	Intravenous
IWL	Insensible water loss
Kg	Kilogram
LONS	Late onset neonatal sepsis
LOS	Late onset sepsis

mmol/L	Millimol per liter
NEC	Necrotizing enterocolitis
NICU	Neonatal intensive care unit
NIRTURE	<b>Neonatal Insulin Therapy in Europe</b>
NRP	Neonatal resussitation program
NVD	Normal vaginal delivery
PDA	Patent ductus arteriosus
PEPCK	phosphoenolpyruvate carboxykinase
PMA	Post menstrual age
P	P value
PROM	Premature rupture of membranes
RDS	Respiratory distress syndrome
ROP	Retinopathy of prematurity
r	Spearman correlation coefficient
SD	Standard deviation
SGA	Small for gestational age
TPN	Total parenteral nutrition
U.S	United states
VLBW	Very low birthweight
WHO	World health organization

# **Introduction**

Very low birth weight (VLBW) infants comprise between 4-8% of live-births but about one-third of deaths during the neonatal period occur in this group of newborns (Fanaroff et al., 2007).

Studies have reported normal outcomes in approximately 73% of these preterm neonates, figures vary widely from country to country with reports of up to 90% survival from developed countries to 40% in the developing world (**Ruegger et al., 2012**).

Although hyperglycemia is common in very low birth weight (VLBW) infants, particularly in extremely low birth weight (ELBW) neonates, still no consensus has been reached on a specific blood sugar level that would define hyperglycemia in neonates (Sabzehei et al., 2014).

Hyperglycemia is defined as two consecutives values >8.3 mmol/L (150 mg/dL) during the first 14 days of life in premature neonates (**Dreyfus et al., 2015**).

The prevalence of hyperglycemia in neonates has been estimated as 20%–88%; wide variations in the reported prevalence result from different definitions, varying birth weights (BW), degree of stress, and volume and rate of intravenous infusions of dextrose water (DW) in studied newborns (Kairamkonda & Khashu, 2008).

Prematurity is an important risk factor in the complex pathogenesis of hyperglycemia. Insulin resistance develops due to a high circulating level of inflammatory markers, cytokines and catecholamines. Consequently, glucose production in the liver is not inhibited. The pancreas needs to produce insulin to compensate, but is probably unable to do so due to immature beta-cells, leading to relative insulin deficiency (**Beardsall & Dunger, 2008**).

Predisposing factors for neonatal hyperglycemia include low birth weight, low gestational age, severity of underlying disease, sepsis, hypoxia, low Apgar scores,

surgery and stress. In addition, administration of the following medications results in an increased risk of hyperglycemia: rapid infusions of intravenous dextrose, intralipid solution, inotropic drugs, theophylline and steroids for Chronic lung Disease (CLD) (Beardsall et al., 2010).

Hyperglycemia causes an osmotic diuresis resulting in dehydration; other associated findings include; late-onset sepsis (LOS), intraventricular hemorrhage (IVH), necrotizing enterocolitis (NEC) and prolonged hospitalization (**Alexandrou et al., 2010**).

### **REVIEW OF LITERATURE**

### **Chapter 1**

### **Introduction on Prematurity**

#### **Definition:**

Preterm birth, defined as birth that occurs on or before the end of the 37th week (259th day) of pregnancy, counting from the first day of the last menstrual period (WHO, 2010).

Preterm birth can be further sub-divided based on gestational age:

- Extremely preterm (<28 weeks)
- Very preterm (28 <32 weeks)
- Moderate preterm (32 <37 completed weeks of gestation).

Moderate preterm birth may be further split to focus on late pre-term birth (34 - <37 completed weeks) (Marlow, 2012).

Babies born before the 34th week of pregnancy have the highest risk for early death and enduring health problems, but recent research has shown that even late preterm infants (at 34 to 36 weeks of pregnancy) have greater health risks than full-term babies (Martin et al., 2009).

#### **Incidence:**

Worldwide,15 million babies born in 2010 were born prematurely, of these preterm births, 84% occurred at 32 to 36 weeks gestational age (GA), 10% occurred at 28 to <32 weeks GA, and 5 percent occurred at <28 weeks GA, more than 1 million died as a result of their prematurity (**Blencowe et al., 2012**).